MSTN: Growth/differentiation factor 8
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Acts specifically as a negative regulator of skeletal muscle growth. .
- Drugs that act on it: 7
- With a US drug page: 1
- Type: Protein
Drugs That Act on It
Approved and clinical-stage drugs ChEMBL records for this target; those with a US approval link to their page| Apitegromab | Approved | Growth/differentiation factor 8 inhibitor | Inhibitor | — |
| Domagrozumab | — | Growth/differentiation factor 8 inhibitor | Inhibitor | — |
| Landogrozumab | — | Growth/differentiation factor 8 inhibitor | Inhibitor | — |
| PF-03446879 | — | Growth/differentiation factor 8 inhibitor | Inhibitor | — |
| Ramatercept | — | Growth/differentiation factor 8 inhibitor | Inhibitor | — |
| Stamulumab | — | Growth/differentiation factor 8 inhibitor | Inhibitor | — |
| Trevogrumab | — | Growth/differentiation factor 8 inhibitor | Inhibitor | — |
Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Myostatin-related muscle hypertrophy
- 0.50
- Varicose veins
- 0.36
- Proximal spinal muscular atrophy
- 0.36
- Bronchopneumonia
- 0.33
- Lung abscess
- 0.33
- Placenta praevia
- 0.16
- Sarcopenia
- 0.13
- Obesity disorder
- 0.13
- Cancer
- 0.12
- Obesity due to melanocortin 4 receptor deficiency
- 0.11
Drugs and mechanisms are from ChEMBL CHEMBL3407325 (CC BY-SA 3.0). Gene name, function (UniProt O14793, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets